溢多利(300381) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 547,080,607.96, representing a year-on-year increase of 21.24%[8] - Net profit attributable to shareholders was CNY 44,136,222.67, an increase of 2.48% year-on-year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 69.95% to CNY 41,438,942.06 compared to the same period last year[8] - The net profit for the period was CNY 107,582,245.37, an increase of 11.37% from CNY 96,600,227.75 year-on-year, driven by the performance of the subsidiary, increased sales in the feed enzyme segment, and reduced interest expenses[21] - Total operating revenue for Q3 2019 was CNY 547,080,607.96, an increase of 21.3% compared to CNY 451,223,197.37 in Q3 2018[42] - Net profit for Q3 2019 reached CNY 58,391,655.24, representing a 12.4% increase from CNY 51,929,066.85 in Q3 2018[43] - The net profit for Q3 2019 reached CNY 3,869,484.12, a significant recovery from a net loss of CNY 7,916,320.44 in Q3 2018[46] - The total comprehensive income attributable to the parent company was CNY 44,136,222.67, compared to CNY 43,068,027.30 in the same period last year[46] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was CNY 245,159,458.95, up 145.42%[8] - Cash flow from operating activities increased significantly to CNY 245,159,458.95, a 145.42% rise from CNY 99,893,884.00 in the previous year, attributed to increased accounts payable and the use of bank acceptance bills for payments[21] - The company's cash and cash equivalents decreased by CNY 711,553,168.29, a decline of 1875.79% compared to an increase of CNY 40,069,637.24 in the previous year, primarily due to repayments of bank loans and investments in various projects[21] - The company's cash and cash equivalents decreased to CNY 90,895,789.33 from CNY 715,330,476.34, indicating a significant reduction in liquidity[38] - The total cash inflow from operating activities was CNY 1,205,116,055.13, compared to CNY 1,137,893,513.33 in the previous year, reflecting an increase of 5.9%[58] - In Q3 2019, the company's operating cash flow net amount was -241,741,112.39 CNY, a significant decline compared to 66,504,849.49 CNY in the previous year[62] - Total cash and cash equivalents at the end of Q3 2019 were 161,718,143.63 CNY, down from 228,149,914.24 CNY in the same period last year, reflecting a decrease of approximately 29.2%[59] Assets and Liabilities - Total assets at the end of the reporting period decreased by 5.07% to CNY 4,557,677,610.60 compared to the end of the previous year[8] - The company's current assets decreased to ¥2,128,445,580.34 from ¥2,587,033,976.05 at the end of 2018, indicating a decline of approximately 17.7%[32] - Total liabilities decreased to ¥1,930,236,940.41 from ¥2,394,425,839.26, a reduction of approximately 19.4%[34] - The company's total equity attributable to shareholders increased to ¥2,355,240,949.66 from ¥2,142,005,405.16, marking a growth of about 9.9%[35] - Total liabilities amounted to CNY 2,394,425,839.26, with current liabilities at CNY 1,442,576,384.69 and non-current liabilities at CNY 951,849,454.57[68] - The company’s total assets as of the end of Q3 2019 were 4,801,120,582.60 CNY, remaining stable compared to the previous year[66] Investments and Expenditures - The company is actively investing in new projects, including a CNY 120 million investment in a new steroid hormone GMP project and a CNY 150 million investment in a food-grade enzyme project[21] - The company reported a significant increase in investment income, which rose to CNY 48,870,201.00 from CNY 23,055,760.35, representing a growth of 111.3%[54] - The company reported a net cash outflow from investment activities of 296,054,984.19 CNY, compared to a net outflow of 154,894,196.33 CNY in the previous year, indicating an increase in investment expenditures[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 429,325,611[12] - The company has implemented its first employee stock ownership plan, involving 170 employees, to enhance employee engagement and retention[22] - The first phase of the employee stock ownership plan was released from restrictions on July 19, 2019, with a total of 9,941,000 shares held, accounting for 2.32% of the company's total share capital[24] - The number of participants in the first phase of the employee stock ownership plan decreased from 162 to 158 due to resignations[24] Research and Development - The company reported a significant increase in research and development expenses, which rose to CNY 28,861,888.10 from CNY 20,022,946.57, marking a 44.1% increase[42] - Research and development expenses increased to CNY 7,284,711.34, up 38.4% from CNY 5,264,517.90 in the previous year[46] - Research and development expenses increased to CNY 17,052,434.85, up from CNY 13,556,031.39, marking a rise of 25.0% year-over-year[54] Regulatory and Compliance - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[28] - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[74] - The company implemented new financial instrument standards starting January 1, 2019, impacting the classification and measurement of financial instruments[68]